Strober; Warren

Patent Applications and Registrations

Patent applications and USPTO patent grants for Strober; Warren.The latest application filed is for "treatment or prevention of an intestinal disease or disorder".

Company Profile

0.13.16

Strober; Warren - Bethesda MD

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Treatment or prevention of an intestinal disease or disorder Grant 10,058,559 - Strober , et al. August 28, 2	2018-08-28
Treatment Or Prevention Of An Intestinal Disease Or Disorder App 20170079987 - Strober; Warren ; et al.	2017-03-23
Methods of treating and preventing inflammatory bowel disease involving IL-13 and NKT cells Grant 9,072,716 - Strober , et al. July 7, 2	2015-07-07
Methods of treating and preventing colitis involving IL-13 and NK-T cells Grant 8,821,866 - Strober , et al. September 2, 2	2014-09-02
Use of muramyl dipeptide (MDP) for treating inflammation Grant 8,603,978 - Strober , et al. December 10, 2	2013-12-10
Methods Of Treating And Preventing Colitis Involving Il-13 And Nk-t Cells App 20120276113 - Strober; Warren ; et al.	2012-11-01
Methods of treating colitis involving IL-13 and NK-T cells Grant 8,173,123 - Strober , et al. May 8, 2	2012-05-08
Treatment Of Cancer Via Targeting Of Il-13 Receptor-alpha2 App 20110268749 - Strober; Warren ; et al.	2011-11-03
Use Of Muramyl Dipeptide (mdp) For Treating Inflammation App 20100292153 - Strober; Warren	2010-11-18
Methods Of Treating And Preventing Colitis Involving Il-13 And Nk-t Cells App 20100143339 - Strober; Warren ; et al.	2010-06-10
Methods of treating and preventing colitis involving IL-13 and NK-T cells Grant 7,666,411 - Strober , et al. February 23, 2	2010-02-23
Compositions and Methods for the Treatment of Inflammatory Bowel Disease Utilizing NF-KappaB Decoy Polynucleotides App 20090214630 - Strober; Warren ; et al.	2009-08-27
Inducible plasmid vector encoding TGF-.beta. and use thereof Grant 7,531,352 - Strober , et al. May 12, 2	2009-05-12
Methods of treating and preventing inflammatory bowel disease involving il-13 and nkt cells App 20090092543 - Strober; Warren ; et al.	2009-04-09
Compositions and methods for the treatment of inflammatory bowel disease utilizing NF-kappaB decoy polynucleotides App 20060258604 - Strober; Warren ; et al.	2006-11-16
Inducible plasmid vector encoding tgf-beta and use thereof App 20060234964 - Strober; Warren ; et al.	2006-10-19
Methods for enhancing oral tolerance and treating autoimmune disease using inhibitors of interleukin-12 App 20060228360 - Strober; Warren ; et al.	2006-10-12
Methods of treating and preventing colitis involving il-13 and nk-t cells App 20060024306 - Strober; Warren ; et al.	2006-02-02
Mucosal cytotoxic T lymphocyte responses App 20050232897 - Berzofsky, Jay A. ; et al.	2005-10-20
Methods of using CR3 and CR4 ligands for inhibiting interleukin-12 to treat autoimmune disease App 20040136994 - Kelsall, Brian ; et al.	2004-07-15
Mucosal cytotoxic T lymphocyte responses Grant 6,749,856 - Berzofsky , et al. June 15, 2	2004-06-15
Methods for enhancing oral tolerance and treating autoimmune disease using inhibitors of interleukin-12 App 20030228311 - Strober, Warren ; et al.	2003-12-11
Methods of treating colitis using STAT-4 anti-sense oligonucleotides Grant 6,479,465 - Strober , et al. November 12, 2	2002-11-12
Methods of treating colitis using STAT-4 anti-sense oligonucleotides App 20020077308 - Strober, Warren ; et al.	2002-06-20
Methods for enhancing oral tolerance and treating autoimmune disease using inhibitors of interleukin-12 App 20010051159 - Strober, Warren ; et al.	2001-12-13
Methods of treating established colitis using antibodies against IL-12 Grant 5,853,697 - Strober , et al. December 29, 1	1998-12-29

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.